ACM
NMRA icon

ADAR1 Capital Management’s Neumora Therapeutics NMRA Stock Holding History

ADAR1 Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.5K Sell
33,100
-17,500
-35% -$45.3K ﹤0.01% 296
2025
Q4 		$90.6K Buy
+50,600
New +$111K 0.01% 255
2025
Q2 		– Sell
-26,108
Closed -$26.1K – 228
2025
Q1 		$26.1K Sell
26,108
-42,500
-62% -$72.8K ﹤0.01% 193
2024
Q4 		$727K Buy
+68,608
New +$822K 0.15% 93

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

ADAR1 Capital Management's NMRA Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Neumora Therapeutics (NMRA) stake by 35% in Q1 2026, selling an estimated $45.3K and leaving 33,100 shares worth $64.5K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

ADAR1 Capital Management first reported a position in NMRA in Q4 2024 and has held it in 4 quarters since. The position peaked at $727K in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • ADAR1 Capital Management held 33,100 shares of Neumora Therapeutics worth $64.5K as of Q1 2026.
  • ADAR1 Capital Management sold 17,500 Neumora Therapeutics shares in Q1 2026, an estimated $45.3K.
  • Neumora Therapeutics made up ﹤0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #296 holding.
  • ADAR1 Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Neumora Therapeutics position peaked at $727K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.